{"name":"WuXi AppTec","slug":"wuxi-apptec","ticker":"2359.HK","exchange":"HKEX","domain":"wuxiapptec.com","description":"WuXi AppTec Co., Ltd. is a Chinese provider of contract research, development, and manufacturing, services for the pharmaceutical and life-sciences industry, headquartered in Shanghai, China. The company operates research and manufacturing facilities in Asia, North America, and Europe.","hq":"Shanghai, China","founded":2000,"employees":"33834","ceo":"Ge Li","sector":"CRO / CDMO","stockPrice":124.6,"stockChange":-0.3,"stockChangePercent":-0.24,"marketCap":"$377.4B","metrics":{"revenue":43420823552,"revenueGrowth":18.2,"grossMargin":48.9,"rdSpend":0,"netIncome":17820823552,"cash":42340507648,"dividendYield":0.85,"peRatio":16.6,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Lynparza patent cliff ($1.2B at risk)","drug":"Lynparza","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"Keytruda patent cliff ($14.5B at risk)","drug":"Keytruda","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-08-04","type":"deal","headline":"WuXi AppTec and BioNTech Announce Strategic Partnership","summary":"WuXi AppTec and BioNTech have entered into a strategic partnership to accelerate the development of mRNA-based vaccines and therapeutics.","drugName":"","sentiment":"positive"},{"date":"2022-02-22","type":"earnings","headline":"WuXi AppTec Reports Fourth Quarter and Full Year 2021 Financial Results","summary":"WuXi AppTec reported revenue of $1.4 billion for the fourth quarter of 2021, a 25% increase year-over-year.","drugName":"","sentiment":"neutral"},{"date":"2021-12-27","type":"regulatory","headline":"WuXi AppTec Receives FDA Approval for New Manufacturing Facility","summary":"WuXi AppTec has received FDA approval for its new manufacturing facility in China, expanding its capacity for commercial-scale production.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQd2g4enozdWJ1a2VUV0VISW9wNWZMb1hVMVF4UF9CdS1jemFWbWhXTWxSWUtMYWtNNkV0b1RBSTRBNVRLT3k5TGhMSTZRM2c2WG5BRHJicG5Vd1ZIMmpxQmUtellELU96RmtpQUR6THdvdWZuemt4WE1TZWtSNVRDR3FSSDViOTVfRUFPd05hWEVvLXBQeVFLSU9ET3h6aUlzMTBXTFVtX2txU1B6Z0JFak9feG0?oc=5","date":"2026-03-23","type":"pipeline","source":"Smartkarma","summary":"WuXi AppTec (2359 HK): Core Business Drives 2025 Performance; Momentum to Continue - Smartkarma","headline":"WuXi AppTec (2359 HK): Core Business Drives 2025 Performance; Momentum to Continue","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxQbk84TzM1eWhnaXU3cWkwaXlYLTlteUk1RXB4SUp1aWVzaEZaeDlXUGlZeTVXUE9YVXlEM3hCb29GeTduempGZks3TFBVMXc0RkNvTG4wYTJ4QTQ5cW1seUVOLWl0T1VkYkF1VWF4bVI4MU1ocGdlbGNOTGtCWUhURGQ1NHpuZHRaalE2YTR6ZEtsUHRTNS1JSmZSck8zdWJBaDExSFBMbGJlVlpxcVdaRF9KY2hnUjZFbl9jLVRUOGlsaU03WHNpZU44cXk3Zmpfb0daQ0JQMk85NnNtb0JTaGxzdVRLbW1I?oc=5","date":"2025-10-27","type":"earnings","source":"BioPharma APAC","summary":"WuXi AppTec Reports RMB32.86 Billion Revenue for First Three Quarters of 2025, Up 18.6% Year-on-Year - BioPharma APAC","headline":"WuXi AppTec Reports RMB32.86 Billion Revenue for First Three Quarters of 2025, Up 18.6% Year-on-Year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOUlFhd0pnTFRKa1pEd1Z6bjNZeVdRX0Z6dGs4Wi1pcFpILUdnQW5KcHFxSXhYZFQ1LWk4ZG5GQUQ1Tlh4LWl3YTNrMFhEVVNRYlg4ajYwQXJ4Uk9XbE5tUnJtckdzSER4WW41VFdvRHdXVmlpcldzbTRzWXBrNUZRX1BUNDVvM3pYeHV0YkltZEE0VUNTTnhTWXZaU0g4amRNOTh4WU1lU1U?oc=5","date":"2025-06-18","type":"pipeline","source":"The Standard (HK)","summary":"China pharma projects disrupted by Sino-US tensions - The Standard (HK)","headline":"China pharma projects disrupted by Sino-US tensions - The Standard (HK)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNcmthVWNSRE1BSjJUZ09LaEx2SEJYcC15OGVBM2NNaVNyOU5TU2RQRmt2dVBSUHYyalpZWGg0cEluWlJZZGVkeXhyUjEzRUR0OWoyUzhqNG5rSU9keGVHQmhaeEdYX3lmLUNKR0EwYUM2bklxcVpRbGExRXRsQlA3THRzSU43X0FUeXBfeA?oc=5","date":"2025-04-17","type":"pipeline","source":"thebambooworks.com","summary":"WuXi group wrestles with uncertainty over pharma tariffs - thebambooworks.com","headline":"WuXi group wrestles with uncertainty over pharma tariffs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOcXNCRzR2bnZ1NkVsdF9UeUZ4UkZrU2h3dWppVFphRllvT3dDNUhjbFpzR2psOTZVM1JrSjI1ZThLeFhLUVF5MXl4YVhoU3FyYU94Q1otMVh6S2FnVlExRVRkSlNpT2JoV1R1WU5yN3NKaUdJQm9GUmtsYUVOUVlSQkN6Um9ES1g5bUE?oc=5","date":"2024-04-11","type":"pipeline","source":"thebambooworks.com","summary":"InSilico seeks IPO boost to get AI drugs over the line - thebambooworks.com","headline":"InSilico seeks IPO boost to get AI drugs over the line","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE1ia1ZoS3A1TkZPb1VzVktPRU5Lbm05U0tyRmtabmNXY3ZDdllqX203X1l6cGFwYVgyR2NZYzBRZWV6c04ycGxFd1U3Z0RyMGtTOTQ5cXhfZkl4NVRRVkE3NDRn?oc=5","date":"2021-10-29","type":"pipeline","source":"TradingView","summary":"WuXi AppTec Co., Ltd. Class H Trade Ideas — HKEX:2359 - TradingView","headline":"WuXi AppTec Co., Ltd. Class H Trade Ideas — HKEX:2359","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE85NFNWOWM5dFRfRENtc0FvNkZTVjcwOVlrMmpzOF94WEx5ZmFMOUdONDA0UU02amtKTTh2a2hqWFlIR1R1TGhzMG55Zl96NUEteUJueURB?oc=5","date":"2021-02-24","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Pharmaron Beijing Co., Ltd. (3759.HK) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Pharmaron Beijing Co., Ltd. (3759.HK) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE82YzRNc0VZaTJoUU50a2xVZ0w0Rl9WSE85Mm8wVkEzbWJYb1Y0QWNBMFF3YjZOdlMxTkd2Mi1CZmtDSHlib3JncGJWdy1UdGFDV1RuSzJR?oc=5","date":"2020-09-09","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Hangzhou Tigermed Consulting Co., Ltd (3347.HK) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Hangzhou Tigermed Consulting Co., Ltd (3347.HK) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE43dlFFVmNQeVZQVXB2Q1BNOExOTlFjTGMyeXRSYkRUMEVPR3dZUm1tTnFRLTNXZldBczZTRnBvYlU2a1BhSkoyb0xkZ0VHOXZjR0EzVUVvdTM?oc=5","date":"2018-12-12","type":"pipeline","source":"WuXi AppTec","summary":"WuXi AppTec Lists H Shares on the Hong Kong Stock Exchange - WuXi AppTec","headline":"WuXi AppTec Lists H Shares on the Hong Kong Stock Exchange","sentiment":"neutral"}],"patents":[{"drugName":"Lynparza","drugSlug":"olaparib","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"Keytruda","drugSlug":"pembrolizumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":14500000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Charles River Laboratories","IQVIA","Laboratory Corporation of America"],"therapeuticFocus":["Oncology","Infectious Diseases","Rare Diseases"],"financials":null,"yahoo":{"currentPrice":124.6,"previousClose":124.9,"fiftyTwoWeekHigh":129.9,"fiftyTwoWeekLow":44.3,"fiftyTwoWeekRange":"44.3 - 129.9","fiftyDayAverage":115.31,"twoHundredDayAverage":106.52,"beta":0.54,"enterpriseValue":339286294528,"forwardPE":16.1,"priceToBook":4.09,"priceToSales":8.69,"enterpriseToRevenue":7.81,"enterpriseToEbitda":17.25,"pegRatio":0,"ebitda":19664728064,"ebitdaMargin":45.3,"freeCashflow":10029419520,"operatingCashflow":17203161088,"totalDebt":8420113408,"debtToEquity":10.5,"currentRatio":3.21,"returnOnAssets":11.2,"returnOnEquity":25.8,"analystRating":"1.2 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":21,"targetMeanPrice":148.02,"targetHighPrice":174.6,"targetLowPrice":129.11,"dividendRate":1.06,"payoutRatio":0.15,"fiveYearAvgDividendYield":1.19,"exDividendDate":1757289600,"insiderHeldPercent":12.8,"institutionHeldPercent":57.4,"sharesOutstanding":510476909,"floatShares":2581009614,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":7.52,"epsForward":7.73,"revenuePerShare":15.19,"bookValue":30.46,"officers":[{"age":58,"name":"Dr. Ge  Li Ph.D.","title":"Co-Founder, Executive Chairman, President & CEO"},{"age":56,"name":"Dr. Minzhang  Chen Ph.D.","title":"Co-CEO & Executive Director"},{"age":56,"name":"Dr. Qing  Yang Ph.D.","title":"Co-CEO & Executive Director"},{"age":51,"name":"Ms. Ming  Shi","title":"Senior VP & CFO"},{"age":56,"name":"Mr. Zhaohui  Zhang","title":"COO of China, Executive VP & Executive Director"},{"age":null,"name":"Mr. Ruijia  Tang","title":"IR Director"},{"age":null,"name":"Dr. Howard  Wu J.D.","title":"Senior Vice President of Legal Department & Human Resources Department"},{"age":null,"name":"Mr. Tao  Guo Ph.D.","title":"Senior Vice President of RCS IPM"}],"industry":"Diagnostics & Research","irWebsite":"","website":"https://www.wuxiapptec.com","phone":"86 21 5046 1111"}}